Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349584 | 1.00 | ALDH1A1 (0.56) | ALDH1A1ALOX15TP53CA1CA2 | |
| SCHEMBL645757 | 0.84 | ALDH1A1 (0.54) | ALDH1A1ALOX15TP53CA1CA2 | |
| SCHEMBL9692043 | 0.84 | ALDH1A1 (0.50) | ALDH1A1ALOX15TP53CA1CA2 | |
| SCHEMBL28072667 | 0.84 | ALDH1A1 (0.50) | ALDH1A1ALOX15TP53CA1CA2 | |
| SCHEMBL343535 | 0.82 | CES2 (0.68) | ALDH1A1ALOX15CES2CES1TAS1R3 | |
| SCHEMBL283203 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TP53CA1CA2SMN1; SMN2 | |
| SCHEMBL30396748 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TP53CA1CA2SMN1; SMN2 | |
| SCHEMBL654794 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TP53CA1CA2MAOB | |
| SCHEMBL3621421 | 0.80 | MAOB (0.47) | ALDH1A1TP53CA1CA2CES2 | |
| SCHEMBL11669995 | 0.80 | ALDH1A1 (0.54) | ALDH1A1ALOX15CES2CES1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-114907338-B | Nitrogen-containing polycyclic condensed ring compound, pharmaceutical composition, preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-114907338-A | Nitrogen-containing polycyclic fused ring compound, and pharmaceutical composition, preparation method and application thereof | 北京志健金瑞生物医药科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022166642-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京志健金瑞生物医药科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-110937994-B | Method for synthesizing 2, 4-dichloro-6-fluorobenzoyl chloride by two-step chlorination process | 浙江大洋生物科技集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3636641-B1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3636641-B1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-12-08 | — | — | EP | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| EP-0026469-B1 | DIBENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1984-11-28 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| US-4360525-A | NEUROLEPTIC AGENTS, ANTIDEPRESSANTS, SLEEP PROMOTERS | SANDOZ LTD. (CH) | 1982-11-23 | — | — | US | disclosed |
| EP-0026469-A1 | Dibenzazepine derivatives, their production and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4056/4885ALOX15 3374/4885TP53 134/4885 |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | ALDH1A1 3753/4885ALOX15 507/4885TP53 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.